Cellectis S.A. - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi CLLS

Stable licensing revenue from Cellectis S.A. (CLLS) supports the balance sheet, as confirmed by the EBITDA cash flow; meanwhile, the value of 0.00 characterizes this level. Geopolitical fragmentation and logistical disruptions between the US and Europe are hindering global trials. However, a strategic alliance with a pharma behemoth is accelerating the launch of allogeneic CAR-T therapies through external funding.

CLLS Bathi operasional EBITDA Cellectis (23.11.2025 - 10.11.2026)

Ringkesan rincian data analitis Cellectis (CLLS)

- nilai pasar lan prakiraan target analis:

Rega bursa Cellectis SA|CLLS - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar Cellectis S.A.|CLLS - Nilai Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham Cellectis S.A.|CLLS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku cellectis.com|CLLS - Aset Agregat Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- data bathi lan kelipatan valuasi:

CLLS - Bathi resik perusahaan|Prakiraan bathi resik Cellectis S.A.|CLLS - Pangali P/E|Rasio prakiraan rega marang bathi Cellectis SA|CLLS - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Cellectis S.A.|CLLS - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan Cellectis S.A.|CLLS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan cellectis.com|CLLS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Cellectis S.A.

Pambiji fundamental perusahaan:Cellectis S.A.

Analyzing fundamental risks requires monitoring real cash flow from operating activities, which measures a business's ability to generate profit before depreciation and taxes. The operating earnings trend for Cellectis S.A. (CLLS) reflects the efficiency of monetizing CAR-T technology licenses, allowing investors to distinguish temporary market dips from a systemic decline in revenues from pharmaceutical partners and oncology centers.

Karo sapa Cellectis S.A. saingan